+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Gut peptides in the treatment of diabetes mellitus



Gut peptides in the treatment of diabetes mellitus



Expert Opinion on Investigational Drugs 13(3): 177-188



It has been known for at least one century that agents secreted from the intestine during meal absorption regulates glucose assimilation. Extensive research during the past three decades has identified two gut hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP, also known as gastric inhibitory polypeptide) that are important in postprandial glucose metabolism. Both peptides are incretins; they are secreted during carbohydrate absorption and increase insulin secretion. Since they are potent insulin secretagogues, GIP and GLP-1 have received considerable attention as potential diabetes therapeutics. However, only GLP-1 exerts insulinotropic properties when administered to patients with Type 2 diabetes. Both GLP-1 and GIP are rapidly inactivated in the circulation by the enzyme dipeptidyl peptidase IV (DPP-IV). The application of GLP-1 into clinical practice has been delayed due to the need to develop compounds that overcome this rapid inactivation. Two approaches have been taken to utilise the insulinotropic and glucose-lowering actions of GLP-1 as an antidiabetic agent: the development of DPP-IV-resistant analogues and the inhibition of DPP-IV. This review focuses on the physiology of GLP-1 and GIP and the advances that have been made thus far in developing treatments based on these physiological incretins for Type 2 diabetes.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049178557

Download citation: RISBibTeXText

PMID: 15013938

DOI: 10.1517/13543784.13.3.177


Related references

Diabetes mellitus : Advance of research and medical care. III. Treatment for diabetes mellitus and another disease complications. 4. Diabetes mellitus with endocrine diseases - disease state, diagnosis and treatment. Nihon Naika Gakkai Zasshi 85(4): 530-535, 1996

Gut peptides and type 2 diabetes mellitus treatment. Current Diabetes Reports 3(5): 365-372, 2003

Novel Peptides: An Alternative Approach for the Treatment of Diabetes Mellitus. Current Drug Therapy 2(3): 196-204, 2007

Diabetes mellitus.An advance on diagnosis and treatment.2.Treatment of diabetes mellitus.8.A knack of the education for patients with diabets mellitus. Nihon Naika Gakkai Zasshi 80(8): 1238-1242, 1991

Diabetes mellitus.An advance on diagnosis and medical treatment.3.Recent topics surrounding diabetes mellitus.4.Gene diagnosis of diabetes mellitus. Nihon Naika Gakkai Zasshi 80(8): 1256-1258, 1991

Diabetes mellitus : an advance on diagnosis and treatment.1.Disease state and diagnosis of diabetes mellitus.1.A concept and diagnostic criterion of diabetes mellitus. Nihon Naika Gakkai Zasshi 80(8): 1171-1175, 1991

Diabetes mellitus : an advance of diagnosis and treatment.2.Medical treatment of diabetes mellitus.5.How to control boundary type and glucose tolerance abnormality. Nihon Naika Gakkai Zasshi 80(8): 1220-1225, 1991

Diabetes mellitus : Advance of research and medical care. III. Treatment for diabetes mellitus and another disease complications. 5. Treatment and diagnosis in pregnancy. Nihon Naika Gakkai Zasshi 85(4): 536-540, 1996

Treatment with marine collagen peptides modulates glucose and lipid metabolism in Chinese patients with type 2 diabetes mellitus. Applied Physiology Nutrition and Metabolism 35(6): 797-804, 2010

Diabetes mellitus : an advance on diagnosis and medical treatment.2.Medical treatment of diabetes mellitus.6.Differential diagnosis of coma in patients with diabetic mellitus and its therapy. Nihon Naika Gakkai Zasshi 80(8): 1226-1231, 1991

Diabetes mellitus related common medical disorders : recent progress in diagnosis and treatment. Topics: I. Pathophysiology, diagnosis and treatment: 3. Primary aldosteronism, resistant hypertension and diabetes mellitus. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 102(4): 850-855, 2013

Diabetes mellitus related common medical disorders recent progress in diagnosis and treatment. Topics I. Pathophysiology, diagnosis and treatment; 4. Diabetes mellitus and infectious diseases. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 102(4): 856-861, 2013

The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study. Circulation 127(2): 180-187, 2013

Diabetes mellitus : Advance of research and medical care. III. Treatment for diabetes mellitus and another disease complications. 3. Hepatic diseases. Nihon Naika Gakkai Zasshi 85(4): 525-529, 1996

GLP-1-Agonisten kombiniert mit Basalinsulin in der Behandlung des Diabetes mellitus Typ 2; GLP-1 agonists combined with basal insulin in the treatment of type 2 diabetes mellitus;. Der Diabetologe 10(8): 662-664, 2014